Table 3.
Dose- and time-dependent cytotoxicity of GO-based nanocarriers in different cell lines.
| Nanoparticle | Cell Type | Dose (µg/mL)/Dependency | Time (Day)/Dependency | ||
|---|---|---|---|---|---|
| GONR (PEG-DSPE) [122] | HeLa; MCF-7; SKBR; NIH3T3 | 10−400 | Y | 0.5−2 | Y |
| GO | PMO; J774A.1; LLC; MCF-7; HepG2; HUVEC [117] | 0−20 | Y | 1, 2, and 4 | - |
| HDF [129] | 5, 10, 20, 50, and 100 | Y | 1, 2, 3, 4, and 5 | Y | |
| A549 [130,131] | 10, 25, 50, 100, and 200 | N | 1, 2, and 3 | N | |
| HepG2 [132] | 4, 8, and 16 | Y | 1 and 3 | Y | |
| GO, GOD and GOP a [114] | MCF-7 | 2.4, 24, and 48 (μg/cm2) | Y | 1, 2, and 3 | N |
| GO-DEX-Apt-CUR b [90] | 4T1; MCF-7 | Up to 300 | Y | 1 and 2 | N |
| Lipid-rGO [119] | MDA-MB-231 | 10, 50, and 100 | Y | 1 and 2 | Y |
| MCF-7; MCF 10-A | N | N | |||
| rGO [118] | MDA-MB-231; ZR-75-1 | 25−300 | Y | 1 and 2 | Y |
| MCF-7; Hs 578T; T-47D | N | N | |||
| Graphene/SWCNT [128] | PC12 | 0.01, 0.1, 1, 10, and 100 | Y | 1−24 h | Y |
a GO modified with DAB-AM-16 and PAMAM dendrimers. b Dextran, ssDNA aptamer, and curcumin.